Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, James Carmichael, Mark E. Robson et al.|The Lancet|2010Cited by 1.6k
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJoachim von Pawel, Richard J. Gralla, J P Kleisbauer et al.|Journal of Clinical Oncology|1999Cited by 960